ArticleJournal of the advanced practitioner in oncology2025
Improving the Appropriate Prescribing of Olanzapine for Chemotherapy-Induced Nausea and Vomiting: A Quality Improvement Initiative for the Outpatient Oncology Practice.
Article in Journal of the advanced practitioner in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Updated American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) antiemetic guidelines recommend olanzapine for the prophylactic treatment of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC). Inadequate treatment of CINV can result in compounding physical sequelae, ultimately affecting patients' tolerance and recovery throughout chemotherapy treatment. Regional Michigan Oncology Quality Consortium (MOQC) data have identified a wide range of compliance rates in the appropriate prescribing of olanzapine. Literature has shown that olanzapine is safe and effective for the treatment of acute and delayed CINV. Purpose: The purpose of this quality improvement (QI) project was to improve the compliance rate of appropriate prescribing of olanzapine for CINV for adult patients receiving HEC within the project site's outpatient oncology clinic. Methods/Procedures: The project was based on the Plan-Do-Study-Act (PDSA) model and implemented in an outpatient oncology clinic in a Midwestern urban area over a 6-month time period. A multidisciplinary and interactive education program was delivered to providers. Pre- and post-intervention data were collected by impartial, independent auditors. At monthly provider staff meetings, a presentation was provided to prescribers supplying information on the updated antiemetic guideline recommendations and the pharmacodynamics of olanzapine. An olanzapine frequently asked questions (FAQ) sheet was also provided to reinforce the reviewed material. Results: Data collected following implementation showed an increase in appropriate prescribing of olanzapine from 82.05% to 94.74% ( Conclusion/Interpretations: Audit data obtained following the implementation of the QI project revealed a statistically significant improvement, which supported the hypothesis that providing education based on the PDSA model is an effective method to improve the compliance rate of appropriate olanzapine prescribing for CINV in patients receiving HEC. The result reflects the growing body of evidence confirming the validity of the PDSA model.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.